02 September 2017 : Clinical Research
The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy
DOI: 10.12659/MSM.903301
Med Sci Monit 2017; 23:4230-4240
HTML version available soon